Chronic kidney disease (CKD) is a general term for a set of heterogeneous disorders that negatively affect the function and structure of the kidney. CKD is characterized by a progressive loss of function and can lead to end-stage renal disease (ESRD), necessitating dialysis. The most common causes of CKD are diabetes and hypertension. As the prevalence of hypertension and diabetes continues to increase, so too does the prevalence of CKD and the cost to national healthcare systems for treating these patients. Thus, the commercial opportunity for drugs with proven efficacy in delaying the progression of this condition and/or treating its symptoms is considerable.

Because of the lack of disease-modifying agents for CKD, treatment is aimed at minimizing the symptoms and complications arising from progressively diminished kidney function. The most common complications are renal anemia, hyperphosphatemia, and secondary hyperparathyroidism. This content takes a comprehensive look at the CKD therapy market, including treatment practices, unmet need, the early- and late-stage therapy pipelines, the likely impact of emerging therapies, and reimbursement and access restrictions.

Table of contents

  • Disease Landscape & Forecast
    • Executive Summary
      • Introduction
        • Key Findings
    • Market Outlook
      • Market Outlook
        • Key Findings
        • Expert Insight
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Chronic Kidney Disease?
        • What Factors Are Constraining the Market for Chronic Kidney Disease?
      • Drug-Class-Specific Trends
        • Erythropoietin-Stimulating Agents
        • Phosphate Binders
        • Iron Supplements
        • Calcium Mimetics
        • Active Vitamin D Analogues
        • Potassium Binders
        • Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors
        • Endothelin Receptor Antagonists
        • Mineralocorticoid Receptor Antagonists
        • Sodium-Glucose Cotransporter-2 Inhibitors
    • Forecast
    • Etiology and Pathophysiology
      • Etiology and Pathophysiology
        • Key Findings
        • Expert Insight
        • Disease Overview
        • Pathophysiology
        • Etiology
        • Key Pathways and Drug Targets
    • Epidemiology Overview
      • Introduction
        • Key Findings
        • Expert Insights
        • Overview
      • Epidemiology Populations
        • Total Prevalent Cases of Chronic Kidney Disease and Staging
        • Diagnosed Prevalent Cases of Chronic Kidney Disease
        • Drug-Treated Cases of Chronic Kidney Disease
    • Current Treatment Overview
      • Introduction
        • Key Findings
        • Expert Insight
        • Treatment Overview
      • Treatment Goals
        • Key Physician Insights on Clinical Trial End Points for Chronic Kidney Disease
      • Key Current Therapies
        • Overview
        • Renin-Angiotensin-Aldosterone System Inhibitors
        • Erythropoietin-Stimulating Agents
        • Iron Supplementation
        • Phosphate Binders
        • Active Vitamin D Analogues and Calcium Mimetics
        • Potassium Binders
        • Dialysis Treatment of End-Stage Renal Disease
      • Medical Practice
        • Overview
        • Treatment Guidelines
        • Drug Selection
        • Region-Specific Treatment
    • Unmet Need Overview
      • Introduction
        • Key Findings
        • Expert Insight
      • Attainment of Unmet Needs
        • Current Attainment of Unmet Needs in Chronic Kidney Disease
        • Future Attainment of Unmet Needs in Chronic Kidney Disease
    • Emerging Therapies Overview
      • Introduction
        • Key Findings
        • Expert Insight
        • Pipeline Overview
      • Late-Phase Pipeline Analysis
        • Notable Developments in the Late-Phase Pipeline for Chronic Kidney Disease
      • Key Emerging Therapies
        • Calcium Mimetics
        • Active Vitamin D Analogues
        • Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors
        • Potassium Binders
        • Endothelin Receptor Antagonists
        • Mineralocorticoid Receptor Antagonists
        • Sodium-Glucose Co-Transporter 2 Inhibitors
        • Sodium-Hydrogen Antiporter 3 Inhibitors
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Chronic Kidney Disease
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • U.S. Reimbursement Dynamics
        • Reimbursement Dynamics in Renal Anemia in the United States: Current and Future
      • U.S. Access & Reimbursement Considerations for Emerging Therapies
        • Access & Reimbursement Considerations for Emerging Renal Anemia Therapies in the United States
    • Methodology
      • Methodology
        • Market Forecast Methodology
        • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • Pricing, Dosing, Days of Therapy, and Compliance Assumptions
    • Appendix
      • Experts Interviewed
      • Chronic Kidney Disease Bibliography

Author(s): Caitlin Koris, MSPH

Caitlin Koris, MSPH, is a business insights analyst on the cardiovascular, metabolic, and renal disorders team at Decision Resources Group. She has developed expertise in chronic kidney disease and related disorders such as bone and mineral metabolism, renal anemia, hyperkalemia, diabetic nephropathy, and kidney transplant. Prior to joining DRG, Caitlin was a clinical research monitor for oncology phase I and II trials. She obtained her in public health/health services research (MSPH) from Emory University, where she focused on pharmacoeconomics/outcomes research and healthcare policy. She has conducted research at the Centers for Disease Control and at the Food and Drug Administration.